News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Celsion Corporation (CLN) Reports Second Quarter 2013 Financial Results and Provides HEAT Study Update


8/8/2013 7:29:27 AM

Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

LAWRENCEVILLE, N.J., Aug. 8, 2013 /PRNewswire/ -- Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced financial results for the second quarter ended June 30, 2013 and an update from its retrospective analysis of the clinical trial results for ThermoDox®, Celsion's proprietary heat-activated liposomal encapsulation of doxorubicin.

Hey, check out all the research scientist jobs. Post your resume today!

Read at Reuters


comments powered by Disqus
Reuters
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES